Which drug best prevents pancreatitis in kids after ERCP?

NCT ID NCT05664074

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 192 children having an ERCP procedure to see which drug—rectal indomethacin or IV ketorolac—better prevents post-ERCP pancreatitis. Both are anti-inflammatory medicines given before the procedure. The goal is to find the most effective option for kids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
rectal indomethacin and intravenous ketorolac
What this could lead to
If this trial shows one drug is better, it could help doctors choose the best way to prevent pancreatitis after ERCP in children.
What could go wrong
This is a completed Phase 4 trial with 192 children, but results may not apply to all patients. Both drugs have known side effects like bleeding risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-ERCP ACUTE PANCREATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.